Nucala

Nucala

mepolizumab

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Mepolizumab
Indications/Uses
Add-on maintenance treatment of severe eosinophilic asthma in patients ≥12 yr.
Dosage/Direction for Use
SC Adult & adolescent ≥12 yr 100 mg once every 4 wk.
Contraindications
Special Precautions
Should not be used to treat acute asthma exacerbations. Asthma-related adverse events or exacerbations may occur. Abrupt discontinuation of corticosteroid after initiation of Nucala therapy is not recommended. Acute & delayed systemic reactions, including hypersensitivity reactions. Patients w/ pre-existing helminth infections. Pregnancy & lactation. Childn <12 yr.
Adverse Reactions
Headache. Pharyngitis, lower resp tract infection, UTI; nasal congestion; upper abdominal pain; eczema; back pain; hypersensitivity reactions; pyrexia, local inj site reactions, administration-related reactions.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03DX09 - mepolizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Nucala powd for soln for inj 100 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in